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Abstract
Background. IgA nephropathy (IgAN) can be complicated
by nephrotic syndrome. Because the spontaneous resolution
of heavy proteinuria is rare, corticosteroid therapy should be
considered in such cases, particularly when IgAN is com-
bined with minimal-change disease. Here, we report our ex-
perience of spontaneous remission of nephrotic syndrome
in patients with IgAN and the long-term outcomes of these
patients.
Methods. Two hundred and thirty-three patients with
biopsy-proven IgAN were enrolled between January 2001
andMarch 2009. Demographic, clinical and laboratory data
were collected retrospectively based on medical records. In
addition, pathologic findings were reviewed for glomerular
and tubulointerstitial lesions. Outcome data for complete or
partial remission, spontaneous remission, relapse, deteri-
oration of renal function, and end-stage renal disease were
recorded.
Results. Twenty-four patients (10.3%) presented nephrotic
syndrome. Among them, five patients underwent spontan-
eous remission within 6 months after the presentation of
nephrotic syndrome. Interestingly, spontaneous remission
occurred even in two patients who had elevated serum cre-
atinine levels and advanced renal damage. During follow-
up, neither recurrence nor relapse occurred, and no patients
showed progressive deterioration of kidney function.
Conclusions. This study suggests that spontaneous remis-
sion of nephrotic syndrome may occur in any stage of IgAN
and carries a favourable long-term outcomewithout relapse.
Given the possibility of under-reported cases, large-scale
studies are required, and careful attention should be paid
to such complicated cases.
Keywords: IgA nephropathy; nephrotic syndrome; spontaneous
remission
Introduction
IgA nephropathy (IgAN) is the most common primary
glomerulonephritis and is an important cause of end-stage
renal disease (ESRD) worldwide [1]. It is well known that
IgAN slowly progresses to chronic kidney disease in all
patients, and 25–30% of most published cohorts required
renal replacement therapy within 20–25 years of presenta-
tion. In addition, <10% of all patients with IgAN had
complete resolution of urinary abnormalities [1,2].
Even though a mild to moderate degree of proteinuria
is commonly seen at different stages of IgAN, nephrotic
syndrome rarely occurs. When IgAN is complicated by
minimal-change disease (MCD), a trial of high-dose cor-
ticosteroids should be considered because proteinuria re-
mits promptly in response to this therapy [3,4]. Although
spontaneous remission is often reported in adult-onset
MCD [5], it is uncommon in patients with nephrotic syn-
drome combined with IgAN. A literature review revealed
that only a few cases of spontaneous resolution of heavy
proteinuria in IgAN with conservative treatment have been
documented [6,7]. The clinical characteristics of patients
with this uncommon feature of IgAN are poorly understood
due to the limited number of cases reported. Therefore, we
report our experience and the long-term outcome of such
patients and also provide a review of previous reports.
Materials and methods
Between January 2001 and March 2009, a total of 233 patients were di-
agnosed with biopsy-proven IgAN at NHIC Medical Center, Ilsan Hos-
pital. Accordingly, all cases included in this study met the following
criteria: (i) predominant mesangial deposition of IgA at least 1+ (~4+)
on immunofluorescent staining, (ii) the presence of mesangial electron-
dense deposits on electron microscopic studies, and (iii) the absence of
other systemic inflammatory diseases such as systemic lupus erythemato-
sus. Patients with Henoch–Schonlein purpura were excluded in this study.
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Among the 233 patients, 23 were lost to follow-up. Demographic and clin-
ical datawere reviewed retrospectively for age, gender, medical history, pre-
senting symptoms, medications, time to remission and follow-up duration.
We collected laboratory data including 24-h urinary protein excretion,
urinary protein-to-creatinine ratio, serum creatinine, albumin and total
cholesterol levels. The estimated glomerular filtration rate (eGFR) was
calculated using the four-variable Modification of Diet in Renal Disease
study (MDRD) formula in adults and the Schwartz and Counahan–Barratt
equation in children [8]. Pathologic findings were also reviewed for the
number of glomeruli and the presence of mesangial hypercellularity, glo-
merulosclerosis, crescent, endocapillary proliferation, tubular atrophy,
interstitial fibrosis and foot process effacement. All cases were reported
based on the Haas classification system [9]. Nephrotic syndrome was di-
agnosed based on the presence of generalized oedema, heavy proteinuria
of >3.5 g/day, hypoalbuminaemia of <3.5 g/dL, and/or hypercholesterol-
aemia [10]. Complete remission was defined as the absence of proteinuria
(urinary protein excretion <0.3 g/day) and trace or negative urinary albu-
min on a dipstick test with the disappearance of oedema and normalization
of biochemical findings such as hypoalbuminaemia and hypercholestero-
laemia. Partial remissionwas defined as a reduction in proteinuria by >50%
from baseline and <3.5 g/day. Recurrence was defined as the reappearance
of significant proteinuria ≥1.0 g/day or >3+ urinary albumin on the dip-
stick test and oedema. During follow-up, complete or partial remission,
spontaneous remission, recurrence, deterioration of renal function, and
ESRD were recorded.
Statistical analysis
Statistical analysis was performed using SPSS version 13.0 (SPSS Inc.,
Chicago, IL, USA). All data are expressed asmedianswith ranges. Because
the sample size was small, non-parametric tests were conducted. Variables
were compared between the two groups using the Mann–Whitney U-test
and Fisher’s exact test. Significance was defined as a P-value <0.05.
Results
Characteristics of patients with IgA nephropathy presenting
nephrotic syndrome
Of the 233 patients with biopsy-proven IgAN, nephrotic
syndrome was present in 24 patients (10.3%) (Table 1).
All 24 patients complained of generalized oedema. None
of them presented gross haematuria. The median age was
43 (9–74)years, and 17 patients (70.8%) were male. Seven
patients (29.2%) had hypertension, and the median serum
creatinine concentration and 24-h urinary protein excretion
values were 1.1 (0.3–2.3)mg/dL and 6.5 (3.8–15.6)g/day,
respectively. Renin–angiotensin system (RAS) blockers
such as angiotensin-converting enzyme inhibitors (ACEis)
or angiotensin II receptor blockers (ARBs) were prescribed
in all patients except for one paediatric patient. Of the
seven patients with prior hypertension, two had already
been on RAS blockers, and the doses of RAS blockers were
increased after the presentation of nephrotic syndrome. In
the other five patients, who had been taking calcium channel
blockers or beta blockers, RAS blockers were substituted or
added. Themedian time interval between the presentation of
Fig. 1. The change in the urine protein/creatinine ratio during follow-up
in five patients with IgA nephropathy combined with nephrotic syndrome.
All patients achieved spontaneous remission within 6 months of the onset
of nephrotic syndrome.
Table 1. Clinical characteristics in patients with IgA nephropathy combined with nephrotic syndrome
All Steroid use Non-steroid use
Number of patients 24 12 12
Age (years) 43 (9–74) 42 (9–74) 44 (19–61)
Gender (male, %) 17 (70.8%) 8 (66.7%) 9 (75.0%)
Hypertension (n, %) 7 (29.2%) 4 (33.3%) 3 (25.0%)
Systolic BP (mmHg) 125 (100–150) 123 (100–145) 125 (110–150)
Diastolic BP (mmHg) 78 (70–90) 78 (70–90) 79 (70–90)
Serum creatinine (mg/dL) 1.1 (0.3–2.3) 1.1 (0.3–2.3) 1.2 (0.7–2.1)
eGFR (mL/min/1.73 m2) 71.2 (27.9–193.5) 73.4 (27.9–193.5) 67.8 (34.5–97.2)
24-h protein excretion (g/day) 6.5 (3.8–15.6) 7.0 (5.1–13.4) 5.2 (3.8–15.6)
Total cholesterol (mg/dL) 288 (241–637) 314 (242–637) 281 (241–430)
Serum albumin (g/dL) 2.7 (1.1–3.4) 2.2 (1.1–3.3) 2.9 (2.1–3.4)
Interval between presentation and biopsy (days) 6 (1–210) 4 (2–210) 7 (1–30)
Pathologic findings (Haas)
I 5 2 3
II 2 1 1
III 6 5 1
IV 8 3 5
V 3 1 2
Clinical outcomes
Complete remission 12 7 5
Partial remission 9 4 5
ESRD 3 1 2
All data are expressed as medians with ranges.
Spontaneous remission of nephrotic syndrome in IgA nephropathy 1571
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nephrotic syndrome and the time of the renal biopsy was 6
(1–210) days. A paediatric patient who was empirically
treated with corticosteroids at the first onset of nephrotic
syndrome underwent a renal biopsy 210 days after the initial
presentation because of frequent relapses and persistent
microscopic haematuria. In all other patients, renal biopsies
were performed within 1 month after presentation.
Among 24 patients, 12 (50.0%) were treated with corti-
costeroids. With the exclusion of the paediatric patient men-
tioned above, 11 of these patients received RAS blockers
prior to the administration of corticosteroids. The median
interval between RAS blocker treatment and corticosteroids
treatment was 10 (0–88) days. In detail, 9 of these 11 pa-
tients took corticosteroids shortly after RAS blockers treat-
ment (i.e. within 2–3 weeks), whereas corticosteroids were
initiated in 2 patients 61 and 88 days after RAS blockers
treatment due to persistent heavy proteinuria. The initial
regimen was oral prednisolone at 1 mg/kg of body weight
per day (maximum 80mg/day) for 4–8 weeks. Prednisolone
was continued at the initial dose for four more weeks when
complete remission was attained, followed by subsequent
tapering (e.g. dose reduction by 5–10 mg/week until
reaching 5 mg/day). However, the treatment duration varied
depending on the pattern of response to corticosteroids or
side effects. The median duration of corticosteroids
treatment was 275 (126–911) days. Among those treated
with corticosteroids, complete and partial remission were
achieved in seven (58.3%) and four (33.3%) patients,
respectively. Recurrence occurred in three of the seven
patients with complete remission, one of whom experienced
recurrence during the tapering of corticosteroids. Cyclo-
sporin was added in four patients: one with no response to
corticosteroids, another with frequent relapses, and the
other two patients with partial remission. Only one patient
who did not respond to corticosteroids eventually pro-
gressed to ESRD.
The other 12 patients were not treated with corticoste-
roids because 5 underwent spontaneous remission shortly
after the diagnosis, 4 did not agree to receive corticoster-
oids, and 3 were suffering from a gastric ulcer, pulmonary
tuberculosis, and a hepatitis B infection. In the five pa-
tients with spontaneous remission, proteinuria decreased
by 65–90% within 3 months after the onset of nephrotic
syndrome (Figure 1). Of the remaining seven patients,
five underwent partial remission, while two had persistent
proteinuria and slowly progressed to ESRD.
Clinical features, pathologic findings and outcomes in
patients with IgA nephropathy combined with nephrotic
syndrome who underwent spontaneous remission
The five patients who underwent spontaneous remission
showed similar features to those who achieved complete
remission with corticosteroid treatment. When baseline
parameters at the presentation of nephrotic syndrome were
compared between the two groups, there were no significant
differences in age, gender, 24-h urinary protein excretion,
serum creatinine and pathologic findings (Tables 2 and 3).
In addition, other serologic markers such as hepatitis B sur-
face antigen positivity, C3, C4 and serum IgA levels were
comparable between the two groups (data not shown). All
patients showed diffuse or multifocal foot process efface-
ment on electron microscopy, except for one patient with
spontaneous remission, who presented generalized oedema
and 24-h urinary protein excretion of 10.6 g, but underwent
spontaneous remission before renal biopsy (Table 3, Pa-
tient 1). Interestingly, spontaneous remission occurred for
all subclasses of IgAN. Three patients who underwent re-
mission had a Haas classification of I or II, whereas the re-
maining two patients had a Haas classification of IV and V,
respectively (Table 3). In addition, the elapsed time to re-
mission was not different between patients with spontan-
eous remission and those treated with corticosteroids
who achieved complete remission. In five patients with
spontaneous remission, no relapse or recurrence occurred,
while three patients in the corticosteroid treatment group
Table 3. Pathologic findings in patients with complete remission after steroid use and in those with spontaneous remission
Patient
Pathology
(Haas)
No. of
glomeruli
Global
sclerosis
(glomeruli
number)
Segmental
sclerosis
(glomeruli
number)
Mesangial
hypercellularity
Endocapillary
proliferation
Tubular
atrophy
Interstitial
fibrosis
Foot process
effacement
Immunofluorescence
activity
Complete remission to steroid
1 I 28 0 0 − − − − Diffuse IgA 1+
2 I 7 0 0 − − − − Diffuse IgA 2+, C3 +/−
3 IV 15 4 7 >50% + Moderate Moderate Multifocal IgA 1+, C3 1+
4 II 35 0 3 Minimal − − − Diffuse IgA 1+, C3 1+
5 III 7 0 3 <50% − Mild − Multifocal IgA 2+, C3 +/−
6 III 16 1 2 <50% − Mild Mild Multifocal IgA 2+, C3 1+
7 IV 30 11 16 >50% + Mild Mild Multifocal IgA 1+, C3 1+
Spontaneous remission
1 I 8 0 2 − − − − Normal IgA 2+, C3 1+
2 I 18 0 0 − − − − Diffuse IgA 1+
3 II 6 0 2 − − − − Diffuse IgA 2+, C3 1+/−
4 V 16 7 5 >50% + Mild Mild Diffuse IgA 1+, C3 1+/−
5 IV 6 2 2 >50% − Moderate Moderate Multifocal IgA 3+, C3 1+/−
Spontaneous remission in previous reports (1 and 2, Wu et al.; 3, Hogg et al.)
1 II 26 1 0 Minimal − − − Diffuse IgA deposit, C3 2+
2 III 9 NA NA <50% − Focal Focal Diffuse IgA 4+, C3 3+
3 II 60 0 0 − − − − Diffuse IgA 3+, C3 2+
Spontaneous remission of nephrotic syndrome in IgA nephropathy 1573
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experienced recurrence. Renal function remained stable in
both groups during the follow-up period (Table 2).
Discussion
Themost common clinical feature of IgAN is asymptomatic
haematuria with or without proteinuria. However, in rare in-
stances, this can be complicated by nephrotic syndrome,
and ~5% of patients with IgAN simultaneously display
MCD [3,4]. Similar to those with adult-onset idiopathic
MCD, many, but not all, of these patients respond well to
corticosteroids [11]. Recently, we have encountered several
cases of spontaneous remission of nephrotic syndrome
combined with IgAN. This study provides a summary of
such cases, and based on our experience, we have attempted
to define the clinical characteristics of this uncommon
manifestation of IgAN.
To date, five IgAN patients who presented nephrotic syn-
drome underwent spontaneous remission at this centre.
However, because these patients were treated with ACEis
or ARBs, the term ‘spontaneous’may not be completely ac-
curate. However, complete disappearance of proteinuria is
very unlikely to be achieved by RAS blocker treatment
alone because it has been reported that RAS blockers can
decrease urinary protein excretion by 30–40% from the
baseline at best, even though the extent of decrease is di-
verse [12,13]. In addition, the improvement in clinical and
laboratory parameters such as oedema, heavy proteinuria
and elevated serum cholesterol levels occurred within
6 months after presentation in these patients. Moreover,
spontaneous remission occurred regardless of the subclass
of IgAN. Surprisingly, heavy proteinuria disappeared spon-
taneously in two patients with diffuse proliferative or ad-
vanced glomerulonephritis and elevated serum creatinine
concentrations. Our findings contrast with the results of pre-
vious reports [6,7] in several ways. First, all patients in our
study underwent spontaneous remission within a short
period of time after the onset of nephrotic syndrome, where-
as complete remission was delayed for up to 2 years in the
previous reports (Table 2). In fact, heavy proteinuria de-
creased spontaneously by >80% within 1–3 months after
the presentation of nephrotic syndrome in all of the study
subjects (Figure 1). Second, in previous reports, all patients
displayed less severe pathologic lesions. Although the Haas
classification system was not available at that time, the
IgAN cases in the earlier studies can be classified as class
II or III when such a classification system was applied on
the basis of the pathologic findings described in the previ-
ous reports. In contrast, in our study, spontaneous remission
occurred even in patients with an advanced subclass of
IgAN. As suggested in the previous reports, MCD might
have been present coincidentally in Patient 1–3. However,
the pathologic findings in Patient 4 and 5 were not compa-
tiblewith the definition ofMCD. It is possible that the heavy
proteinuria in these two patients could be due to other forms
of nephrotic syndrome or advanced glomerular injury
caused by IgAN per se. Even if this is the case, how-
ever, spontaneous disappearance of heavy proteinuria is
very unusual when glomerulosclerosis and inflammation
are clearly evident. Acute insult to podocytes irrespect-
ive of chronic mesangial injury may have been superim-
posed on top of underlying IgAN and have resolved
spontaneously. However, the underlying mechanism re-
quires further investigation.
Interestingly, patients who underwent spontaneous re-
mission had similar features to those who achieved
complete remission with corticosteroid therapy. Although
detailed statistical analysis was not feasible due to the small
number of cases in both groups, baseline parameters
appeared to be comparable between the two groups with
respect to age, gender, 24-h urinary protein excretion, serum
creatinine levels and the pathologic findings (Tables 2
and 3). Furthermore, elapsed time to remission was also
similar in the two groups. These findings may complicate
the choice of therapeutic options in clinical practice; be-
cause clinical parameters are not distinguishable between
the two groups, it is uncertain whether corticosteroid ther-
apy should be postponed for a certain amount of time based
on the expectation of spontaneous remission of nephrotic
syndrome in patients with IgAN. As Hogg and Savino sug-
gested, therapeutic trials in these patients may provide mis-
leading conclusions if the resolution of nephrotic syndrome
is falsely attributed to corticosteroid treatment rather than
spontaneous remission [7]. As long as nephrotic syndrome
is not promptly resolved, delaying corticosteroid therapy
cannot be justified due to undesirable complications during
the heavy proteinuric period, particularly when patients
have severe symptoms or are at risk of complications such
as renal vein thrombosis. However, spontaneous remission
can be expected in patients who show a substantial decrease
in heavy proteinuria without the use of corticosteroids
shortly after the onset of nephrotic syndrome, as observed
in our subjects.
Our study had several shortcomings. First, this study was
retrospective in nature, and only a small number of patients
were evaluated. Therefore, whether our findings can be
generalized needs to be further investigated. In particular,
our data should be interpreted with caution because ad-
vanced pathologic findings were observed in only two pa-
tients, and the small number of glomeruli in some patients
may not be sufficient to evaluate the severity of glomerular
injury. Second, because one patient with spontaneous remis-
sion had a short follow-up duration, the favourable progno-
sis of this patient may not be conclusive. However, the other
patients with spontaneous remission in our study and those
described in previous reports did not show deterioration of
renal function without recurrence. Therefore, it is likely that
these patients did indeed have a favourable outcome. Third,
the chance of coincidental MCD cannot be completely ex-
cluded. Nevertheless, even though highly selective protein-
uria is not consistently observed in adult MCD [14], data on
the selectivity index of our subjects suggest that the inci-
dence of coincidental MCDwas unlikely to be high. Finally,
24-h urine collection was not available for constant monitor-
ing of proteinuria during the follow-up. Urine was obtained
when assessing remission after a urinary dipstick test for
proteinuria became negative or trace. However, 24-h urine
collection is burdensome and is therefore not routinely
checked; thus, the urine protein-to-creatinine ratio is usu-
ally performed in the setting of outpatient clinics to monitor
proteinuria, given the finding that random urine protein-
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to-creatinine ratios can be reliably used to assess the degree
of proteinuria [15].
In conclusion, our results suggest that spontaneous re-
mission of nephrotic syndrome may occur in any subclass
of IgAN, and patients with spontaneous remission may
have favourable outcomes without relapse. Although a de-
tailed analysis to identify factors associated with spontan-
eous remission could not be performed due to the limited
number of cases, spontaneous remission of nephrotic syn-
drome in IgAN is noteworthy. Given the possibility of
under-reported cases, large-scale studies are required, and
careful attention should be paid to such complicated cases.
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Effect of furosemide on left ventricular mass in non-dialysis chronic
kidney disease patients: a randomized controlled trial
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Abstract
Background. In chronic kidney disease (CKD), loop diure-
tics correct volume-dependent hypertension, but their effect
on left ventricular mass index (LVMI) is unknown.
Methods. Forty hypertensive CKD patients (estimated cre-
atinine clearance 60–15 mL/min/1.73 m²), treated with
renin–angiotensin system (RAS) inhibitors, were rando-
mized to receive furosemide or non-diuretic antihyperten-
sive treatment (control group). Office blood pressure (BP)
<130/80 mmHg was pursued in both groups. Primary end
point was the reduction of LVMI after 52 weeks. Secondary
aims were to verify safety related to furosemide treatment
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